The Extraordinary Dr. Koffman, Who Beat Leukemia.
Dr. Brian Koffman is extraordinary, in many ways. He’s extraordinary in the medical sense because, after twelve years of battling blood cancer, doctors can...
GeoVax (GOVX) Conference Call at 4:30 ET, the 29th.
GeoVax to Host Conference Call at 4:30 PM ET
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
ATLANTA, GA, Feb....
Vaxart (VXRT) Gains $171 Million in Market Value After $9.2 Million Award from Project...
Vaxart Closes $10 Million Secondary on January 16th @0.65.
Vaxart Receives $9 Million Award from Barda on January 19th.
Shares trades From a Low of $0.55...
GeoVax to Present at the 2024 BIO CEO & Investor Conference
ATLANTA, GA, Feb. 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial!
Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants
We were having cocktails at a fancy restaurant last night with a hedge fund manager, who manages...
GeoVax Labs (GOVX) JP Morgan 2024 Healthcare Conference Transcript.
ILLUSTRATION 3 |MISSION AND STRATEGY
Our mission: One is to innovate. The other one is to differentiate. The other one is to accelerate and finally...
Revive Therapeutics (RVVTF) $0.02, Explores the Use of Bucillamine for Long COVID.
Bucillamine is one of the most amazing drugs (in our opinion), which was repurposed from its original use as an anti-inflammatory for use with...
Adding GeoVax (GOVX) $3.32 to Reverse Stock Split Watch List.
Okay, Here's Our First Name for the Reverse Stock Split, Watch List. We'll Venture to Have 10 Names Added to Watch List Within 30...
ATCC Announces $87 Million Award for Project NextGen for Vaccines, from Barda.
ATCC, the world’s premier biological materials management and standards organization, today announced a five-year, $87 million award from the Biomedical Advanced Research and Development...
Adding Geovax (GOVX) to 2024 Biotech Watch List.
GEOVAX (GOVX) $0.32
We added this to the Watch List earlier in the week and then AFTER speaking to CEO David Dodd and the Head...
Latest article
Cabaletta (CABA) Surges 44% on Massive Volume Spike.
Biotech 12 Pack Off to Nice Start..
Cabaletta up 35%, GeoVax up 75%, and Replimune up 62%. All since late April!
Biotech Stock Review is...
GeoVax (GOVX) Surges 51% on Massive Volume Spike.
MonkeyPox and Gedeptin Related News Spark New Investor Interest.
MARKET BRIEF
On a quiet Wednesday afternoon, the 29th, while we were nearing completion of an updated...
Paving Past Obstacles on the Path to US Biosecurity
GeoVax’s CEO calls on government support to bolster domestic biotechnology and keep pace with China.
National biosecurity has become a frequent topic of conversation in...
